2005•Expert Opinion on Therapeutic PatentsRequires access

Inhibitors of Aurora kinases for the treatment of cancer

Daniele Fancelli, Jürgen Moll

Abstract

Aurora protein kinases are key players in different steps during mitosis and their activity is required for correct cell division. The inhibition of Aurora kinases is regarded as a promising approach for the development of novel anticancer agents. In the last few years several templates for ATP-competitive kinase inhibition have been successfully developed towards the inhibition of Aurora kinases, and the first compounds have recently entered clinical studies. This review summarises the patent literature up until March 2005 and the characteristics of the low molecular weight Aurora inhibitors described so far.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Kinase, Aurora kinase, Aurora inhibitor, Mitosis, Protein-Serine-Threonine Kinases, Aurora A kinase, Aurora B kinase, Cancer research